1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Fulminant Staphylococcal Infections

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Authors: Yves Gillet1, Thomas Henry3, Francois Vandenesch4
  • Editors: Vincent A. Fischetti6, Richard P. Novick7, Joseph J. Ferretti8, Daniel A. Portnoy9, Miriam Braunstein10, Julian I. Rood11
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Pediatric Emergency, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, F-69677, Bron, France; 2: CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, University of Lyon, F-69007, Lyon, France; 3: CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, University of Lyon, F-69007, Lyon, France; 4: CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, University of Lyon, F-69007, Lyon, France; 5: IAI, Institut des Agents Infectieux, National Reference Center for Staphylococci, Hospices Civils de Lyon, Hôpital de la Croix Rousse, F-69004 Lyon, France; 6: The Rockefeller University, New York, NY; 7: Skirball Institute for Molecular Medicine, NYU Medical Center, New York, NY; 8: Department of Microbiology & Immunology, University of Oklahoma Health Science Center, Oklahoma City, OK; 9: Department of Molecular and Cellular Microbiology, University of California, Berkeley, Berkeley, CA; 10: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, NC; 11: Infection and Immunity Program, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Australia
  • Source: microbiolspec October 2018 vol. 6 no. 5 doi:10.1128/microbiolspec.GPP3-0036-2018
  • Received 17 July 2018 Accepted 06 August 2018 Published 11 October 2018
  • Francois Vandenesch, [email protected]
image of Fulminant Staphylococcal Infections
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Fulminant Staphylococcal Infections, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/6/5/GPP3-0036-2018-1.gif /docserver/preview/fulltext/microbiolspec/6/5/GPP3-0036-2018-2.gif
  • Abstract:

    Fulminant staphylococcal infection indicates an explosive, intense, and severe infection occurring in a patient whose previous condition and antecedent would never have caused any anticipation of life-threatening development. This includes necrotizing pneumonia, necrotizing fasciitis, and to some extent toxic shock syndrome and infective endocarditis. In the three former diseases, toxin production plays a major role whereas in the latter (fulminant presentation of infective endocarditis), association with any particular toxinic profile has never been demonstrated. This article reviews the clinical, pathophysiological, and therapeutic aspects of these diseases.

  • Citation: Gillet Y, Henry T, Vandenesch F. 2018. Fulminant Staphylococcal Infections. Microbiol Spectrum 6(5):GPP3-0036-2018. doi:10.1128/microbiolspec.GPP3-0036-2018.

References

1. Patterson CM, Loebinger MR. 2012. Community acquired pneumonia: assessment and treatment. Clin Med (Lond) 12:283–286 http://dx.doi.org/10.7861/clinmedicine.12-3-283.
2. Touchie C, Marrie TJ. 1997. Respiratory tract infections, p 475–492. In Crossley KB, Archer GL (ed), The Staphylococci in Human Disease. Churchill Livingstone, New York, NY.
3. Melish AR. 1998. Coagulase positive staphylococcus, p 1039–1066. In Feigin RD, Cherry JD (ed), Textbook of Pediatric Infectious Disease. WB Saunders, Philadelphia, PA.
4. Jutras R. 1962. Staphylococcie pleuro-pulmonaire du nourrisson. Can Med Assoc J 87:330–335. [PubMed]
5. Klein JO. 1998. Bacterial pneumonias, p 299–310. In Feigin RD, Cherry JD (ed), Textbook of Pediatric Infectious Disease. WB Saunders, Philadelphia, PA.
6. Wallman IS, Godfrey RC, Watson JR. 1955. Staphylococcal pneumonia in infancy. BMJ 2:1423–1427 http://dx.doi.org/10.1136/bmj.2.4953.1423.
7. Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, O’Brien FG, Tenover FC, McDougal LK, Monk AB, Enright MC. 2005. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 365:1256–1258 http://dx.doi.org/10.1016/S0140-6736(05)74814-5.
8. Prevost G, Couppie P, Prevost P, Gayet S, Petiau P, Cribier B, Monteil H, Piemont Y. 1995. Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 42:237–245 http://dx.doi.org/10.1099/00222615-42-4-237. [PubMed]
9. Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29:1128–1132 http://dx.doi.org/10.1086/313461. [PubMed]
10. Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, Vandenesch F, Etienne J, Lina G. 2011. Pragmatic management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob Agents 38:457–464 http://dx.doi.org/10.1016/j.ijantimicag.2011.05.003. [PubMed]
11. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J. 2007. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 45:315–321 http://dx.doi.org/10.1086/519263. [PubMed]
12. Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piémont Y, Brousse N, Floret D, Etienne J. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753–759 http://dx.doi.org/10.1016/S0140-6736(02)07877-7.
13. Hsu LY, Koh TH, Anantham D, Kurup A, Chan KP, Tan BH. 2004. Panton-Valentine leukocidin-positive Staphylococcus aureus, Singapore. Emerg Infect Dis 10:1509–1510 http://dx.doi.org/10.3201/eid1008.031088. [PubMed]
14. Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG. 2005. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40:100–107 http://dx.doi.org/10.1086/427148. [PubMed]
15. Holmes A, Ganner M, McGuane S, Pitt TL, Cookson BD, Kearns AM. 2005. Staphylococcus aureus isolates carrying Panton-Valentine leucocidin genes in England and Wales: frequency, characterization, and association with clinical disease. J Clin Microbiol 43:2384–2390 http://dx.doi.org/10.1128/JCM.43.5.2384-2390.2005. [PubMed]
16. Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, Barenkamp SJ, Sievert DM, Srinivasan A, Doherty MC, McDougal LK, Killgore GE, Lopatin UA, Coffman R, MacDonald JK, McAllister SK, Fosheim GE, Patel JB, McDonald LC. 2006. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 12:894–899 http://dx.doi.org/10.3201/eid1206.051141. [PubMed]
17. Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, Finelli L, Beekmann SE, Polgreen PM, Gorwitz R, Hageman J. 2009. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 53:358–365 http://dx.doi.org/10.1016/j.annemergmed.2008.04.027. [PubMed]
18. Chen L, Chavda KD, Solanki M, Mediavilla JR, Mathema B, Schlievert PM, Kreiswirth BN. 2013. Genetic variation among Panton-Valentine leukocidin-encoding bacteriophages in Staphylococcus aureus clonal complex 30 strains. J Clin Microbiol 51:914–919 http://dx.doi.org/10.1128/JCM.03015-12. [PubMed]
19. Lambertz J, Saint-Martin J, Lallemand D, Le Tan Vinh, Huault G, Joly JB, Kachaner J, Rossier A, Thieffry S. 1971. Staphylococcie pleuropulmonaire suraigue du grand enfant. Pediatrie 26:13–30.
20. Olcay L, Seçmeer G, Göğüş S, Akçören Z. 1995. Pathological case of the month. Fatal hemorrhagic staphylococcal pneumonia. Arch Pediatr Adolesc Med 149:925–926 http://dx.doi.org/10.1001/archpedi.1995.02170210099019.
21. Centers for Disease Control and Prevention (CDC). 1999. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus: Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 48:707–710. [PubMed]
22. Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L, Fry A, Hageman J, Gorwitz R, Bresee J, Uyeki T. 2008. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics 122:805–811 http://dx.doi.org/10.1542/peds.2008-1336. [PubMed]
23. Sicot N, Khanafer N, Meyssonnier V, Dumitrescu O, Tristan A, Bes M, Lina G, Vandenesch F, Vanhems P, Etienne J, Gillet Y. 2012. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia-results of a prospective observational study. Clin Microbiol Infect. [PubMed]
24. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. 2008. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 198:1166–1170 http://dx.doi.org/10.1086/592053. [PubMed]
25. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci U S A 106:5883–5888 http://dx.doi.org/10.1073/pnas.0900743106. [PubMed]
26. Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, DeLeo FR, Otto M. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13:1510–1514 http://dx.doi.org/10.1038/nm1656. [PubMed]
27. Diep BA, Stone GG, Basuino L, Graber CJ, Miller A, des Etages SA, Jones A, Palazzolo-Ballance AM, Perdreau-Remington F, Sensabaugh GF, DeLeo FR, Chambers HF. 2008. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J Infect Dis 197:1523–1530 http://dx.doi.org/10.1086/587907. [PubMed]
28. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. 2013. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 13:43–54 http://dx.doi.org/10.1016/S1473-3099(12)70238-4.
29. Diep BA, Gillet Y, Etienne J, Lina G, Vandenesch F. 2013. Panton-Valentine leucocidin and pneumonia. Lancet Infect Dis 13:566 http://dx.doi.org/10.1016/S1473-3099(13)70102-6.
30. Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Höök M, Etienne J, Vandenesch F, Bowden MG. 2007. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315:1130–1133 http://dx.doi.org/10.1126/science.1137165. [PubMed]
31. Spaan AN, Henry T, Thorburn AN, van Rooijen WJM, Badiou C, Aerts P, de Haas CJC, van Kessel KPM, Mackay CR, Vandenesch F, Lina G, van Strijp JAG. 2013. Panton-Valentine leuckocin targets C5A receptors. Cell Host Microbe 13:584–594 http://dx.doi.org/10.1016/j.chom.2013.04.006. [PubMed]
32. Löffler B, Hussain M, Grundmeier M, Brück M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G. 2010. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 6:e1000715 http://dx.doi.org/10.1371/journal.ppat.1000715. [PubMed]
33. Tromp AT, Van Gent M, Abrial P, Martin A, Jansen JP, De Haas CJC, Van Kessel KPM, Bardoel BW, Kruse E, Bourdonnay E, Boettcher M, McManus MT, Day CJ, Jennings MP, Lina G, Vandenesch F, Van Strijp JAG, Jan Lebbink R, Haas PA, Henry T, Spaan AN. 2018. Human CD45 is an F-component-specific receptor for the staphylococcal toxin Panton-Valentine leukocidin. Nat Microbiol 3:708–717 http://dx.doi.org/10.1038/s41564-018-0159-x. [PubMed]
34. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 107:5587–5592 http://dx.doi.org/10.1073/pnas.0912403107. [PubMed]
35. Perret M, Badiou C, Lina G, Burbaud S, Benito Y, Bes M, Cottin V, Couzon F, Juruj C, Dauwalder O, Goutagny N, Diep BA, Vandenesch F, Henry T. 2012. Cross-talk between Staphylococcus aureus leukocidins-intoxicated macrophages and lung epithelial cells triggers chemokine secretion in an inflammasome-dependent manner. Cell Microbiol 14:1019–1036 http://dx.doi.org/10.1111/j.1462-5822.2012.01772.x. [PubMed]
36. Holzinger D, Gieldon L, Mysore V, Nippe N, Taxman DJ, Duncan JA, Broglie PM, Marketon K, Austermann J, Vogl T, Foell D, Niemann S, Peters G, Roth J, Löffler B. 2012. Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol 92:1069–1081 http://dx.doi.org/10.1189/jlb.0112014. [PubMed]
37. Rice TW, Rubinson L, Uyeki TM, Vaughn FL, John BB, Miller RR III, Higgs E, Randolph AG, Smoot BE, Thompson BT, NHLBI ARDS Network. 2012. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 40:1487–1498 http://dx.doi.org/10.1097/CCM.0b013e3182416f23. [PubMed]
38. Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, Smoot E, Rice TW, Loftis LL, Helfaer M, Doctor A, Paden M, Flori H, Babbitt C, Graciano AL, Gedeit R, Sanders RC, Giuliano JS, Zimmerman J, Uyeki TM, Pediatric Acute Lung Injury and Sepsis Investigator’s Network and the National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. 2011. Critically ill children during the 2009–2010 influenza pandemic in the United States. Pediatrics 128:e1450–e1458 http://dx.doi.org/10.1542/peds.2011-0774. [PubMed]
39. Tristan A, Benito Y, Montserret R, Boisset S, Dusserre E, Penin F, Ruggiero F, Etienne J, Lortat-Jacob H, Lina G, Bowden MG, Vandenesch F. 2009. The signal peptide of Staphylococcus aureus Panton Valentine leukocidin LukS component mediates increased adhesion to heparan sulfates. PLoS One 4:e5042 http://dx.doi.org/10.1371/journal.pone.0005042. [PubMed]
40. de Bentzmann S, Tristan A, Etienne J, Brousse N, Vandenesch F, Lina G. 2004. Staphylococcus aureus isolates associated with necrotizing pneumonia bind to basement membrane type I and IV collagens and laminin. J Infect Dis 190:1506–1515 http://dx.doi.org/10.1086/424521. [PubMed]
41. Niemann S, Ehrhardt C, Medina E, Warnking K, Tuchscherr L, Heitmann V, Ludwig S, Peters G, Löffler B. 2012. Combined action of influenza virus and Staphylococcus aureus Panton-Valentine leukocidin provokes severe lung epithelium damage. J Infect Dis 206:1138–1148 http://dx.doi.org/10.1093/infdis/jis468. [PubMed]
42. Lee MH, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD. 2010. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 201:508–515 http://dx.doi.org/10.1086/650204. [PubMed]
43. Shukla SK, Rose W, Schrodi SJ. 2015. Complex host genetic susceptibility to Staphylococcus aureus infections. Trends Microbiol 23:529–536. [PubMed]
44. Ye Z, Vasco DA, Carter TC, Brilliant MH, Schrodi SJ, Shukla SK. 2014. Genome wide association study of SNP-, gene-, and pathway-based approaches to identify genes influencing susceptibility to Staphylococcus aureus infections. Front Genet 5:125 http://dx.doi.org/10.3389/fgene.2014.00125. [PubMed]
45. Nelson CL, Pelak K, Podgoreanu MV, Ahn SH, Scott WK, Allen AS, Cowell LG, Rude TH, Zhang Y, Tong A, Ruffin F, Sharma-Kuinkel BK, Fowler VG Jr. 2014. A genome-wide association study of variants associated with acquisition of Staphylococcus aureus bacteremia in a healthcare setting. BMC Infect Dis 14:83 http://dx.doi.org/10.1186/1471-2334-14-83. [PubMed]
46. Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jägerhofer M, Maierhofer B, Teubenbacher A, Dolezilkova I, Gross K, Banerjee S, Zauner G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Gerngross TU, Nagy E. 2015. Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7:243–254 http://dx.doi.org/10.4161/19420862.2014.985132. [PubMed]
47. Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405–1406 http://dx.doi.org/10.1038/nm1207-1405. [PubMed]
48. Spaan AN, Vrieling M, Wallet P, Badiou C, Reyes-Robles T, Ohneck EA, Benito Y, de Haas CJ, Day CJ, Jennings MP, Lina G, Vandenesch F, van Kessel KP, Torres VJ, van Strijp JA, Henry T. 2014. The staphylococcal toxins γ-haemolysin AB and CB differentially target phagocytes by employing specific chemokine receptors. Nat Commun 5:5438 http://dx.doi.org/10.1038/ncomms6438. [PubMed]
49. Stulik L, Malafa S, Hudcova J, Rouha H, Henics BZ, Craven DE, Sonnevend AM, Nagy E. 2014. α-Hemolysin activity of methicillin-susceptible Staphylococcus aureus predicts ventilator-associated pneumonia. Am J Respir Crit Care Med 190:1139–1148 http://dx.doi.org/10.1164/rccm.201406-1012OC. [PubMed]
50. Carrillo-Marquez MA, Hulten KG, Hammerman W, Lamberth L, Mason EO, Kaplan SL. 2011. Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children’s Hospital. Pediatr Infect Dis J 30:545–550 http://dx.doi.org/10.1097/INF.0b013e31821618be. [PubMed]
51. Lemaître C, Angoulvant F, Gabor F, Makhoul J, Bonacorsi S, Naudin J, Alison M, Faye A, Bingen E, Lorrot M. 2013. Necrotizing pneumonia in children: report of 41 cases between 2006 and 2011 in a French tertiary care center. Pediatr Infect Dis J 32:1146–1149 http://dx.doi.org/10.1097/INF.0b013e31829be1bb. [PubMed]
52. Crémieux A-C, Saleh-Mghir A, Danel C, Couzon F, Dumitrescu O, Lilin T, Perronne C, Etienne J, Lina G, Vandenesch F. 2014. α-Hemolysin, not Panton-Valentine leukocidin, impacts rabbit mortality from severe sepsis with methicillin-resistant Staphylococcus aureus osteomyelitis. J Infect Dis 209:1773–1780 http://dx.doi.org/10.1093/infdis/jit840. [PubMed]
53. Todd J, Fishaut M, Kapral F, Welch T. 1978. Toxic-shock syndrome associated with phage-group-I staphylococci. Lancet 2:1116–1118 http://dx.doi.org/10.1016/S0140-6736(78)92274-2.
54. Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, Fraser DW. 1980. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303:1436–1442 http://dx.doi.org/10.1056/NEJM198012183032502. [PubMed]
55. Schlievert PM, Kim MH. 1991. Reporting of toxic shock syndrome Staphylococcus aureus in 1982 to 1990. J Infect Dis 164:1245–1246 http://dx.doi.org/10.1093/infdis/164.6.1245. [PubMed]
56. Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. 1999. Toxic shock syndrome in the United States: surveillance update, 1979–1996. Emerg Infect Dis 5:807–810 http://dx.doi.org/10.3201/eid0506.990611. [PubMed]
57. Todd JK. 1981. Toxic shock syndrome: scientific uncertainty and the public media. Pediatrics 67:921–923. [PubMed]
58. Mitchell MA, Bisch S, Arntfield S, Hosseini-Moghaddam SM. 2015. A confirmed case of toxic shock syndrome associated with the use of a menstrual cup. Can J Infect Dis Med Microbiol 26:218–220 http://dx.doi.org/10.1155/2015/560959. [PubMed]
59. DeVries AS, Lesher L, Schlievert PM, Rogers T, Villaume LG, Danila R, Lynfield R. 2011. Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics. PLoS One 6:e22997 http://dx.doi.org/10.1371/journal.pone.0022997. [PubMed]
60. Descloux E, Perpoint T, Ferry T, Lina G, Bes M, Vandenesch F, Mohammedi I, Etienne J. 2008. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis 27:37–43 http://dx.doi.org/10.1007/s10096-007-0405-2. [PubMed]
61. Gottlieb M, Long B, Koyfman A. 2018. The evaluation and management of toxic shock syndrome in the emergency department: a review of the literature. J Emerg Med 54:807–814 http://dx.doi.org/10.1016/j.jemermed.2017.12.048. [PubMed]
62. Reingold AL, Hargrett NT, Dan BB, Shands KN, Strickland BY, Broome CV. 1982. Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med 96:871–874 http://dx.doi.org/10.7326/0003-4819-96-6-871. [PubMed]
63. Chesney PJ. 1989. Clinical aspects and spectrum of illness of toxic shock syndrome: overview. Rev Infect Dis 11(Suppl 1):S1–S7 http://dx.doi.org/10.1093/clinids/11.Supplement_1.S1. [PubMed]
64. Andrews MM, Parent EM, Barry M, Parsonnet J. 2001. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis 32:1470–1479 http://dx.doi.org/10.1086/320170. [PubMed]
66. Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E. 1989. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321:1–7 http://dx.doi.org/10.1056/NEJM198907063210101. [PubMed]
67. Centers for Disease Control and Prevention. 1997. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 46(RR-10):1–55.
68. Xu SX, McCormick JK. 2012. Staphylococcal superantigens in colonization and disease. Front Cell Infect Microbiol 2:52 http://dx.doi.org/10.3389/fcimb.2012.00052. [PubMed]
69. Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. 2009. Cytolysins augment superantigen penetration of stratified mucosa. J Immunol 182:2364–2373 http://dx.doi.org/10.4049/jimmunol.0803283. [PubMed]
70. Thomas D, Dauwalder O, Brun V, Badiou C, Ferry T, Etienne J, Vandenesch F, Lina G. 2009. Staphylococcus aureus superantigens elicit redundant and extensive human Vbeta patterns. Infect Immun 77:2043–2050 http://dx.doi.org/10.1128/IAI.01388-08. [PubMed]
71. Ferry T, Thomas D, Bouchut JC, Lina G, Vasselon-Raina M, Dauwalder O, Gillet Y, Vandenesch F, Floret D, Etienne J. 2008. Early diagnosis of staphylococcal toxic shock syndrome by detection of the TSST-1 Vbeta signature in peripheral blood of a 12-year-old boy. Pediatr Infect Dis J 27:274–277 http://dx.doi.org/10.1097/INF.0b013e31815c93a3. [PubMed]
72. Dauwalder O, Venet F, Javouhey E, Badiou C, Gillet Y, Guignant C, Plainvert C, Etienne J, Poyart C, Vandenesch F, Lina G, Monneret G. 2012. Assessment of cellular immune parameters in paediatric toxic shock syndrome: a report of five cases. FEMS Immunol Med Microbiol 66:116–119 http://dx.doi.org/10.1111/j.1574-695X.2012.00990.x. [PubMed]
73. Lappin E, Ferguson AJ. 2009. Gram-positive toxic shock syndromes. Lancet Infect Dis 9:281–290 http://dx.doi.org/10.1016/S1473-3099(09)70066-0.
74. Rödström KE, Elbing K, Lindkvist-Petersson K. 2014. Structure of the superantigen staphylococcal enterotoxin B in complex with TCR and peptide-MHC demonstrates absence of TCR-peptide contacts. J Immunol 193:1998–2004 http://dx.doi.org/10.4049/jimmunol.1401268. [PubMed]
75. Lin YC, Anderson MJ, Kohler PL, Strandberg KL, Olson ME, Horswill AR, Schlievert PM, Peterson ML. 2011. Proinflammatory exoprotein characterization of toxic shock syndrome Staphylococcus aureus. Biochemistry 50:7157–7167 http://dx.doi.org/10.1021/bi200435n.
76. Hopkins PA, Fraser JD, Pridmore AC, Russell HH, Read RC, Sriskandan S. 2005. Superantigen recognition by HLA class II on monocytes up-regulates Toll-like receptor 4 and enhances proinflammatory responses to endotoxin. Blood 105:3655–3662 http://dx.doi.org/10.1182/blood-2004-07-2523. [PubMed]
77. Hopkins PA, Pridmore AC, Ellmerich S, Fraser JD, Russell HH, Read RC, Sriskandan S. 2008. Increased surface Toll-like receptor 2 expression in superantigen shock. Crit Care Med 36:1267–1276 http://dx.doi.org/10.1097/CCM.0b013e31816a0a78. [PubMed]
78. Lansdell LW, Taplin D, Aldrich TE. 1984. Recovery of Staphylococcus aureus from multiple body sites in menstruating women. J Clin Microbiol 20:307–310. [PubMed]
79. Liu H, Gao Y, Yu L-R, Jones RC, Elkins CA, Hart ME. 2011. Inhibition of Staphylococcus aureus by lysostaphin-expressing Lactobacillus plantarum WCFS1 in a modified genital tract secretion medium. Appl Environ Microbiol 77:8500–8508 http://dx.doi.org/10.1128/AEM.06755-11. [PubMed]
80. Malik S, Petrova MI, Imholz NC, Verhoeven TL, Noppen S, Van Damme EJ, Liekens S, Balzarini J, Schols D, Vanderleyden J, Lebeer S. 2016. High mannose-specific lectin Msl mediates key interactions of the vaginal Lactobacillus plantarum isolate CMPG5300. Sci Rep 6:37339 http://dx.doi.org/10.1038/srep37339. [PubMed]
81. Todd JK, Todd BH, Franco-Buff A, Smith CM, Lawellin DW. 1987. Influence of focal growth conditions on the pathogenesis of toxic shock syndrome. J Infect Dis 155:673–681 http://dx.doi.org/10.1093/infdis/155.4.673. [PubMed]
82. Sarafian SK, Morse SA. 1987. Environmental factors affecting toxic shock syndrome toxin-1 (TSST-1) synthesis. J Med Microbiol 24:75–81 http://dx.doi.org/10.1099/00222615-24-1-75. [PubMed]
83. Schlievert PM, Nemeth KA, Davis CC, Peterson ML, Jones BE. 2010. Staphylococcus aureus exotoxins are present in vivo in tampons. Clin Vaccine Immunol 17:722–727 http://dx.doi.org/10.1128/CVI.00483-09. [PubMed]
84. Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, Onderdonk AB. 2005. Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 43:4628–4634 http://dx.doi.org/10.1128/JCM.43.9.4628-4634.2005. [PubMed]
85. Jacquemond I, Muggeo A, Lamblin G, Tristan A, Gillet Y, Bolze PA, Bes M, Gustave CA, Rasigade JP, Golfier F, Ferry T, Dubost A, Abrouk D, Barreto S, Prigent-Combaret C, Thioulouse J, Lina G, Muller D. 2018. Complex ecological interactions of Staphylococcus aureus in tampons during menstruation. Sci Rep 8:9942 http://dx.doi.org/10.1038/s41598-018-28116-3. [PubMed]
86. Morgan MS. 2010. Diagnosis and management of necrotising fasciitis: a multiparametric approach. J Hosp Infect 75:249–257. [PubMed]
87. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352:1445–1453 http://dx.doi.org/10.1056/NEJMoa042683. [PubMed]
88. Jamal N, Teach SJ. 2011. Necrotizing fasciitis. Pediatr Emerg Care 27:1195–1199, quiz 1200–1202 http://dx.doi.org/10.1097/PEC.0b013e31823b583c. [PubMed]
89. Bruun T, Oppegaard O, Kittang BR, Mylvaganam H, Langeland N, Skrede S. 2015. Etiology of cellulitis and clinical prediction of streptococcal disease: a prospective study. Open Forum Infect Dis 3:ofv181 http://dx.doi.org/10.1093/ofid/ofv181.
90. Panton NP, Valentine FCO. 1932. Staphylococcal toxin. Lancet 222:506–508 http://dx.doi.org/10.1016/S0140-6736(01)24468-7.
91. del Giudice P, Blanc V, de Rougemont A, Bes M, Lina G, Hubiche T, Roudière L, Vandenesch F, Etienne J. 2009. Primary skin abscesses are mainly caused by Panton-Valentine leukocidin-positive Staphylococcus aureus strains. Dermatology 219:299–302 http://dx.doi.org/10.1159/000232391. [PubMed]
92. Del Giudice P, Bes M, Hubiche T, Roudière L, Blanc V, Lina G, Vandenesch F, Etienne J. 2011. Clinical manifestations and outcome of skin infections caused by the community-acquired methicillin-resistant Staphylococcus aureus clone ST80-IV. J Eur Acad Dermatol Venereol 25:164–169 http://dx.doi.org/10.1111/j.1468-3083.2010.03731.x. [PubMed]
93. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. 2012. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 55:781–788 http://dx.doi.org/10.1093/cid/cis527. [PubMed]
94. Kao LS, Lew DF, Arab SN, Todd SR, Awad SS, Carrick MM, Corneille MG, Lally KP. 2011. Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. Am J Surg 202:139–145 http://dx.doi.org/10.1016/j.amjsurg.2010.07.041. [PubMed]
95. Fowler VG Jr, Li J, Corey GR, Boley J, Marr KA, Gopal AK, Kong LK, Gottlieb G, Donovan CL, Sexton DJ, Ryan T. 1997. Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients. J Am Coll Cardiol 30:1072–1078 http://dx.doi.org/10.1016/S0735-1097(97)00250-7.
96. del Rio A, Cervera C, Moreno A, Moreillon P, Miro JM. 2009. Patients at risk of complications of Staphylococcus aureus bloodstream infection. Clin Infect Dis 48(Suppl 4):S246e53.
97. Rasmussen RV, Høst U, Arpi M, Hassager C, Johansen HK, Korup E, Schønheyder HC, Berning J, Gill S, Rosenvinge FS, Fowler VG Jr, Møller JE, Skov RL, Larsen CT, Hansen TF, Mard S, Smit J, Andersen PS, Bruun NE. 2011. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteraemia: the value of screening with echocardiography. Eur J Echocardiogr 12:414–420 http://dx.doi.org/10.1093/ejechocard/jer023. [PubMed]
98. Le Moing V, Alla F, Doco-Lecompte T, Delahaye F, Piroth L, Chirouze C, Tattevin P, Lavigne JP, Erpelding ML, Hoen B, Vandenesch F, Duval X, VIRSTA study group. 2015. Staphylococcus aureus bloodstream infection and endocarditis: a prospective cohort study. PLoS One 10:e0127385 http://dx.doi.org/10.1371/journal.pone.0127385. [PubMed]
99. Miro JM, Anguera I, Cabell CH, Chen AY, Stafford JA, Corey GR, Olaison L, Eykyn S, Hoen B, Abrutyn E, Raoult D, Bayer A, Fowler VG Jr, International Collaboration on Endocarditis Merged Database Study Group. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41:507–514 http://dx.doi.org/10.1086/431979. [PubMed]
100. Thuny F, Di Salvo G, Belliard O, Avierinos JF, Pergola V, Rosenberg V, Casalta JP, Gouvernet J, Derumeaux G, Iarussi D, Ambrosi P, Calabró R, Riberi A, Collart F, Metras D, Lepidi H, Raoult D, Harle JR, Weiller PJ, Cohen A, Habib G. 2005. Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 112:69–75 http://dx.doi.org/10.1161/CIRCULATIONAHA.104.493155. [PubMed]
101. Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B, Selton-Suty C, Célard M, Le Moing V, Doco-Lecompte T, Chirouze C, Iung B, Strady C, Revest M, Vandenesch F, Bouvet A, Delahaye F, Alla F, Duval X, Hoen B, AEPEI Study Group. 2012. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey. Clin Infect Dis 54:1230–1239 http://dx.doi.org/10.1093/cid/cis199. [PubMed]
102. Claes J, Liesenborghs L, Peetermans M, Veloso TR, Missiakas D, Schneewind O, Mancini S, Entenza JM, Hoylaerts MF, Heying R, Verhamme P, Vanassche T. 2017. Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall. J Thromb Haemost 15:1009–1019 http://dx.doi.org/10.1111/jth.13653.
103. Hienz SA, Schennings T, Heimdahl A, Flock JI. 1996. Collagen binding of Staphylococcus aureus is a virulence factor in experimental endocarditis. J Infect Dis 174:83–88 http://dx.doi.org/10.1093/infdis/174.1.83.
104. Malachowa N, Kohler PL, Schlievert PM, Chuang ON, Dunny GM, Kobayashi SD, Miedzobrodzki J, Bohach GA, Seo KS. 2011. Characterization of a Staphylococcus aureus surface virulence factor that promotes resistance to oxidative killing and infectious endocarditis. Infect Immun 79:342–352 http://dx.doi.org/10.1128/IAI.00736-10. [PubMed]
105. O’Brien L, Kerrigan SW, Kaw G, Hogan M, Penadés J, Litt D, Fitzgerald DJ, Foster TJ, Cox D. 2002. Multiple mechanisms for the activation of human platelet aggregation by Staphylococcus aureus: roles for the clumping factors ClfA and ClfB, the serine-aspartate repeat protein SdrE and protein A. Mol Microbiol 44:1033–1044 http://dx.doi.org/10.1046/j.1365-2958.2002.02935.x. [PubMed]
106. Panizzi P, Nahrendorf M, Figueiredo JL, Panizzi J, Marinelli B, Iwamoto Y, Keliher E, Maddur AA, Waterman P, Kroh HK, Leuschner F, Aikawa E, Swirski FK, Pittet MJ, Hackeng TM, Fuentes-Prior P, Schneewind O, Bock PE, Weissleder R. 2011. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat Med 17:1142–1146 http://dx.doi.org/10.1038/nm.2423. [PubMed]
107. Que YA, Haefliger JA, Piroth L, François P, Widmer E, Entenza JM, Sinha B, Herrmann M, Francioli P, Vaudaux P, Moreillon P. 2005. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 201:1627–1635 http://dx.doi.org/10.1084/jem.20050125. [PubMed]
108. Salgado-Pabón W, Breshears L, Spaulding AR, Merriman JA, Stach CS, Horswill AR, Peterson ML, Schlievert PM. 2013. Superantigens are critical for Staphylococcus aureus infective endocarditis, sepsis, and acute kidney injury. MBio 4:e00494–e13 http://dx.doi.org/10.1128/mBio.00494-13. [PubMed]
109. Stach CS, Vu BG, Merriman JA, Herrera A, Cahill MP, Schlievert PM, Salgado-Pabón W. 2016. Novel tissue level effects of the Staphylococcus aureus enterotoxin gene cluster are essential for infective endocarditis. PLoS One 11:e0154762 http://dx.doi.org/10.1371/journal.pone.0154762. [PubMed]
110. Ferry T, Thomas D, Genestier AL, Bes M, Lina G, Vandenesch F, Etienne J. 2005. Comparative prevalence of superantigen genes in Staphylococcus aureus isolates causing sepsis with and without septic shock. Clin Infect Dis 41:771–777 http://dx.doi.org/10.1086/432798. [PubMed]
111. Adhikari RP, Ajao AO, Aman MJ, Karauzum H, Sarwar J, Lydecker AD, Johnson JK, Nguyen C, Chen WH, Roghmann MC. 2012. Lower antibody levels to Staphylococcus aureus exotoxins are associated with sepsis in hospitalized adults with invasive S. aureus infections. J Infect Dis 206:915–923 http://dx.doi.org/10.1093/infdis/jis462. [PubMed]
112. Spaulding AR, Satterwhite EA, Lin YC, Chuang-Smith ON, Frank KL, Merriman JA, Schaefers MM, Yarwood JM, Peterson ML, Schlievert PM. 2012. Comparison of Staphylococcus aureus strains for ability to cause infective endocarditis and lethal sepsis in rabbits. Front Cell Infect Microbiol 2:18. [PubMed]
113. DeLeo FR, Kennedy AD, Chen L, Bubeck Wardenburg J, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Martens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN. 2011. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A. 108:18091–18096. [PubMed]
114. Cheung GY, Kretschmer D, Duong AC, Yeh AJ, Ho TV, Chen Y, Joo HS, Kreiswirth BN, Peschel A, Otto M. 2014. Production of an attenuated phenol-soluble modulin variant unique to the MRSA clonal complex 30 increases severity of bloodstream infection. PLoS Pathog 10:e1004298 http://dx.doi.org/10.1371/journal.ppat.1004298. [PubMed]
115. Laabei M, Uhlemann AC, Lowy FD, Austin ED, Yokoyama M, Ouadi K, Feil E, Thorpe HA, Williams B, Perkins M, Peacock SJ, Clarke SR, Dordel J, Holden M, Votintseva AA, Bowden R, Crook DW, Young BC, Wilson DJ, Recker M, Massey RC. 2015. Evolutionary trade-offs underlie the multi-faceted virulence of Staphylococcus aureus. PLoS Biol 13:e1002229 http://dx.doi.org/10.1371/journal.pbio.1002229. [PubMed]
116. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group. 2001. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377 http://dx.doi.org/10.1056/NEJMoa010307. [PubMed]
117. Murray RJ. 2005. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J 35(Suppl 2):S106–S119 http://dx.doi.org/10.1111/j.1444-0903.2005.00984.x. [PubMed]
118. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. 2016. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med 8:357ra124 http://dx.doi.org/10.1126/scitranslmed.aag1153.
119. Rouzic N, Janvier F, Libert N, Javouhey E, Lina G, Nizou JY, Pasquier P, Stamm D, Brinquin L, Pelletier C, Vandenesch F, Floret D, Etienne J, Gillet Y. 2010. Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol 48:1952–1955 http://dx.doi.org/10.1128/JCM.01892-09. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.GPP3-0036-2018
2018-10-11
2018-12-17

Abstract:

Fulminant staphylococcal infection indicates an explosive, intense, and severe infection occurring in a patient whose previous condition and antecedent would never have caused any anticipation of life-threatening development. This includes necrotizing pneumonia, necrotizing fasciitis, and to some extent toxic shock syndrome and infective endocarditis. In the three former diseases, toxin production plays a major role whereas in the latter (fulminant presentation of infective endocarditis), association with any particular toxinic profile has never been demonstrated. This article reviews the clinical, pathophysiological, and therapeutic aspects of these diseases.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Tables

Generic image for table
TABLE 1

Case definition of staphylococcal TSS

Source: microbiolspec October 2018 vol. 6 no. 5 doi:10.1128/microbiolspec.GPP3-0036-2018

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error